Notably, previous studies have reported that intravenous Exenatide (Exendin-4) infusion does not significantly alter fasting glucagon secretion in humans 39 , supporting the expectation that genome editing-mediated Exe4 secretion would similarly exert minimal disruption
In real-world observations, individuals on GLP-1 therapies often fall below dietary benchmarks for: 3,5 Microminerals : magnesium, potassium, calcium, iron, and zinc Vitamins : D, A, E, K, B12, B1 (thiamine), and folate Macronutrients : protein and fiber Phytonutrients : including carotenoids and flavonoids Gastrointestinal effectsincluding nausea, bloating, early satiety, and evolving food aversionsfurther constrict intake variety and volume, amplifying the risk
Postmenopausal cardiovascular complications Evidence from recent studies reported that the occurrence/risk of obesity and metabolic syndrome (MetS) are three times higher in postmenopausal women when compared to the premenopausal women [5]
Experimental studies in animal models have demonstrated that disruption of opioid receptor-mediated neurotransmission leads to a reduction in social behaviors (Ragen et al
Hospitals have used IV routes for decades to correct dehydration, deliver medications and restore electrolytes
